Key result
Heparin-polylysine-copper nanozyme coating inhibits platelet aggregation and suppresses neointimal hyperplasia in preclinical models.
Its licence doesn't allow us to show a copy here.
Why the study?
Vascular implants face challenges of late stent thrombosis and in-stent restenosis, and achieving anticoagulant, pro-endothelialization, and anti-neointimal hyperplasia properties typically requires complex surface modifications.
Does a heparin-polylysine-copper nanozyme coating improve anti-thrombotic efficacy and suppress neointimal hyperplasia in vascular implant models?
Does a heparin-polylysine-copper nanozyme coating improve anti-thrombotic efficacy and suppress neointimal hyperplasia in vascular implant models?
A novel heparin-polylysine-copper nanozyme coating for vascular stents demonstrates promising preclinical efficacy in preventing thrombosis and restenosis by promoting nitric oxide release and endothelialization.
Answers are grounded in this paper and cite their sources.
May enable simpler multifunctional stent coatings; leaves open whether this reduces LST or ISR in clinical use.
Re-establishing blood flow through vascular implants, such as stents, faces significant challenges, including late stent thrombosis (LST) and in-stent restenosis (ISR). Strategies to overcome these issues focus on enhancing stent surfaces with anticoagulant, pro-endothelialization, and anti-neointimal hyperplasia (NIH) properties. However, achieving all of these functionalities typically requires complex surface modifications. In this study, we developed nanozyme particles by assembling heparin, polylysine (PLL) and copper ions, which catalytically release nitric oxide (NO) in situ. A functional coating was then formed on pre-deposited polydopamine (PDA) transition layer. Our nanozyme coating not only exhibits robust anticoagulant activity but also enables sustained, in situ release of NO, a critical gas molecule for maintaining vascular health and patency. In vitro results showed that the coating significantly inhibited platelet aggregation, remarkably prolonged activated partial thromboplastin time (APTT), and selectively promoted endothelial cell growth over smooth muscle cells. Ex vivo blood circulation models confirmed its superior anti-thrombotic efficacy, while in vivo experiments further validated its ability to facilitate endothelial regeneration and suppress NIH. This technology offers significant potential for improving the safety and outcomes of cardiovascular implants.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2025) studied Late stent thrombosis and in-stent restenosis. Heparin-polylysine-copper nanozyme coating was evaluated on Anticoagulant activity, NO release, endothelial cell growth, and suppression of neointimal hyperplasia. A heparin-polylysine-copper nanozyme coating significantly inhibited platelet aggregation, prolonged APTT, promoted endothelial cell growth, and suppressed neointimal hyperplasia in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: